GSK-3 alpha/beta (phospho-Tyr216/Tyr279) Monoclonal Antibody detects endogenous levels of GSK-3 only when phosphorylated at serine 21 of GSK-3alpha or serine 9 of GSK-3beta.
Source
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to the sequence of human GSK-3 alpha. Antibodies are purified by protein A and peptide affinity chromatography.
GSK-3 is a Ser/Thr kinase first identified as an inactivator of Glycogen Synthase. GSK-3 acts as a multifunctional downstream switch that determines the output of numerous signaling pathways. There are two mammalian GSK-3 isoforms encoded by distinct genes, GSK-3 alpha and GSK-3 beta, which are structurally similar, but functionally non-identical. GSK-3a is inhibited by phosphorylation at S21 by Akt and other kinases. GSK-3 alpha and GSK-3 beta share 85% amino acid identity. Dysregulated GSK-3 has been implicated in several diseases including type II diabetes, Alzheimer's disease, bipolar disorder, and cancer.
Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin. GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β. GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development. GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization .
More about: GSK-3 alpha/beta (phospho-Tyr216/Tyr279) Monoclonal Antibody (6D3) sale
Read more: phospho antibody
No comments:
Post a Comment